» Articles » PMID: 2237417

Down-regulation of LFA-1 Adhesion Receptors by C-myc Oncogene in Human B Lymphoblastoid Cells

Overview
Journal Science
Specialty Science
Date 1990 Nov 2
PMID 2237417
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The function of the c-myc gene and its role in tumorigenesis are poorly understood. In order to elucidate the role of c-myc oncogene activation in B cell malignancy, the phenotypic changes caused by the expression of c-myc oncogenes in human B lymphoblastoid cells immortalized by Epstein-Barr virus were analyzed. C-myc oncogenes caused the down-regulation of lymphocyte function-associated antigen-1 (LFA-1) adhesion molecules (alpha L/beta 2 integrin) and loss of homotypic B cell adhesion in vitro. Down-regulation of LFA-1 occurred by (i) posttranscriptional modulation of LFA-1 alpha L-chain RNA soon after acute c-myc induction, and (ii) transcriptional modulation in cells that chronically express c-myc oncogenes. Analogous reductions in LFA-1 expression were detectable in Burkitt lymphoma cells carrying activated c-myc oncogenes. Since LFA-1 is involved in B cell adhesion to cytotoxic T cells, natural killer cells, and vascular endothelium, these results imply functions for c-myc in normal B cell development and lymphomagenesis.

Citing Articles

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy.

de Jonge A, Mutis T, Roemer M, Scheijen B, Chamuleau M Cancers (Basel). 2020; 12(10).

PMID: 33092116 PMC: 7589056. DOI: 10.3390/cancers12103052.


Target gene-independent functions of MYC oncoproteins.

Baluapuri A, Wolf E, Eilers M Nat Rev Mol Cell Biol. 2020; 21(5):255-267.

PMID: 32071436 PMC: 7611238. DOI: 10.1038/s41580-020-0215-2.


Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang S, Moon J, Kwee I Oncotarget. 2016; 7(48):79637-79653.

PMID: 27793034 PMC: 5346742. DOI: 10.18632/oncotarget.12876.


Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Pizzi M, Boi M, Bertoni F, Inghirami G Leukemia. 2016; 30(9):1805-15.

PMID: 27389058 DOI: 10.1038/leu.2016.161.


Brain endothelial dysfunction in cerebral adrenoleukodystrophy.

Musolino P, Gong Y, Snyder J, Jimenez S, Lok J, Lo E Brain. 2015; 138(Pt 11):3206-20.

PMID: 26377633 PMC: 4731416. DOI: 10.1093/brain/awv250.